Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Evgen Pharma. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Evgen Pharma's earnings available for a low price, and how does
this compare to other companies in the same industry?
Evgen Pharma is not considered high growth as it is expected to be loss making for the next 1-3 years.
Unable to determine if Evgen Pharma is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Evgen Pharma's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Dr. Stephen J. Franklin, also known as Steve, serves Chief Executive Officer of Evgen Pharma Plc. He has been an Executive Director at Evgen Pharma plc since October 2, 2014. He has over 20 years’ commercial experience in life science industries, focusing on the commercialisation of new technology. Dr. Franklin served as Chief Executive Officer of Provexis plc (formerly Provexis Limited) until June 2006 and its Acting Director of Research from July 24, 2006 to July 24, 2006. Prior to this, he was a Principal Executive with the ANGLE Technology Group where he was intimately involved in establishing its Life Science Venture business unit and the regional office in the North West of England. He served as an Executive Director of Provexis plc from June 23, 2005 to July 24, 2006. He founded and mentored a number of new life science ventures. He has a B.Sc. in Biology from York university, a PhD in Applied Biochemistry from Nottingham and an MBA with distinction also from Nottingham.
Steve's compensation has been consistent with company performance over the past year.
Steve's remuneration is about average for companies of similar size in Germany.
Management Team Tenure
Average tenure of the
management team in years:
The average tenure for the Evgen Pharma management team is less than 2 years, this suggests a new team.
CEO & Executive Director
CFO & Executive Director
Consultant & Medical Advisor of Oncology
Independent Scientific Advisor
Independent Scientific Advisor
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Evgen Pharma board of directors is less than 3 years, this suggests a new board.
Evgen Pharma plc, a clinical stage drug development company, focuses on the treatment of cancer and neurological diseases. Its core technology is Sulforadex, which include synthetic and stabilized analogues of the naturally occurring compound sulforaphane. The company’s lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer. Evgen Pharma plc was founded in 2007 and is headquartered in Wilmslow, the United Kingdom.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.